The Latest Cardiac and Vascular News
PLANO, Texas, Sept. 16, 2024 /PRNewswire/ — Argon Medical Devices, a leading provider of medical device solutions for Interventional Radiology, Vascular Surgery, Interventional Cardiology, and Oncology procedures, announced the launch of the CLEANER Vac™ Thrombectomy System for the…
Southlake, TX, Sept. 12, 2024 (GLOBE NEWSWIRE) — Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today reported financial results for the first quarter fiscal 2025 ended July 31, 2024 and provided a business update.
New data published in JACC: Heart Failure demonstrate durable benefits in MLWHF and EQ-5D quality of life measures in heart failure patients with reduced ejection fraction
Berlin Heals appoints proven cardiac rhythm management and heart failure leader John Brumfield as Chief Executive Office BERLIN, Sept. 12, 2024 /PRNewswire/ — Berlin Heals Holding AG and its subsidiaries Berlin Heals GmbH and Berlin Heals Corp. which are developing a completely new and…
BEDFORD, Mass.–(BUSINESS WIRE)–SpectraWAVE, Inc., a medical imaging company focused on improving the treatment and outcomes for patients with coronary artery disease (CAD), today announced a $50M Series B funding round led by Johnson & Johnson Innovation – JJDC, Inc. joined by S3 Ventures, Lumira Ventures, SV Health Investors, Deerfield Management, […]
WALLINGFORD, Conn. and TAMPA, Fla., Sept. 11, 2024 /PRNewswire/ — InsiteOne, NewVue.AI, and RADPAIR are thrilled to announce a groundbreaking strategic contract with Aligned Radiology, a leading teleradiology provider. This collaboration combines advanced AI-driven workflow…
SOUTH JORDAN, Utah, Sept. 11, 2024 (GLOBE NEWSWIRE) — Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that clinicians will present updates on two of its pivotal studies during scientific sessions held on September 14 at CIRSE in Lisbon, Portugal.
– Company continuing to advance clinical development of HU6, a novel oral, once-daily Controlled Metabolic Accelerator, in Phase 2 trials to treat obesity-related heart failure and metabolic dysfunction-associated steatohepatitis (MASH) – CHARLOTTESVILLE, Va. and SAN FRANCISCO, Sept. 11,…
TORONTO, Sept. 11, 2024 (GLOBE NEWSWIRE) — Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that Alberta Health Services (AHS) has approved the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI).
